AI Article Synopsis
- * A study involving 89 patients showed that those with ALBI grade 1 were mostly classified as Child-Pugh score 5, while ALBI grade 2 patients had varying liver function, indicating a wider range of liver health in this group.
- * ALBI grade 2B indicated a poorer prognosis compared to grades 1 and 2A, and using this grading system helps better identify which patients are suitable for sorafenib treatment.
Article Abstract
Background: The Albumin-Bilirubin (ALBI) grade has been proposed as a new, simple, and objective method of assessing liver function. However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC).
Methods: We evaluated the correlations between the ALBI grade and Child-Pugh score, adverse events, and survival in 89 patients with advanced HCC who were prospectively treated with sorafenib.
Results: Majority of patients with ALBI grade 1 (14/15 patients, 93%) had a Child-Pugh score of 5. Patients with ALBI grade 2 had a wide range of liver function according to the Child-Pugh scores, with scores of 5, 6, 7, and ≥ 8. We divided ALBI grade 2 patients into ALBI grade 2A and 2B groups according to the median ALBI score among patients with ALBI grade 2. Although no significant difference was observed, the incidence of liver dysfunction in sorafenib-treated patients with ALBI grades 1, 2A, and 2B was 7%, 19%, and 35%, respectively. Overall survival in the ALBI grade 2B group was significantly shorter than that in the ALBI grade 1 and 2A groups. Thus, ALBI grade 2B was an independent predictor of poor prognosis in addition to elevated serum aspartate aminotransferase levels, increased serum alpha-fetoprotein level, and macrovascular invasion.
Conclusion: Sorafenib may be indicated for all patients with advanced HCC and ALBI grade 1 and for some with ALBI grade 2. The subdivision of patients with ALBI grade 2 increases the utility of ALBI in identifying patients indicated for sorafenib therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10637-015-0292-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Up-front resection for hepatocellular carcinoma: Assessing futility in the preoperative setting.
Eur J Surg Oncol
January 2025
Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, United States. Electronic address:
Objective: We sought to develop a predictive model to preoperatively identify patients with hepatocellular carcinoma (HCC) at risk of undergoing futile upfront liver resection (LR).
Methods: Patients undergoing curative-intent LR for HCC were identified from a large multi-institutional database. Futile LR was defined by death or disease recurrence within six months postoperatively.
Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.. Electronic address:
Purpose: Optimal treatment strategies for patients with hepatocellular carcinoma (HCC) with oligoprogression after first-line systemic therapy (FLST) remain undefined. We aimed to determine if maintaining [i.e.
View Article and Find Full Text PDFComparing laboratory toxicity of selective intra-arterial radionuclide therapy for primary and metastatic liver tumors: resin versus glass microspheres.
Ann Nucl Med
January 2025
Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
Objective: To compare the acute (within 30 days of treatment) laboratory toxicities of Yttrium-90 (Y-90) resin and glass microspheres.
Methods: Selective intra-arterial radionuclide therapies (SIRTs) with Y-90 resin and glass microspheres were retrospectively reviewed. Liver-hematological data were collected at baseline and at 1 week and 1 month follow-up.
Prognostic value of albumin-bilirubin grade in patients with cholangiocarcinoma: a systematic review and meta-analysis.
BMC Gastroenterol
January 2025
Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.
Background: Cholangiocarcinoma (CCA) is a type of cancer that develops in the biliary tract. CCA accounts for 10% of primary hepatic cancers and is characterized by its aggressive nature and poor prognosis. This systematic review and meta-analysis aims to assess the prognostic value of the novel hepatic function assessment measure known as albumin-bilirubin (ALBI) grade in patients with CCA.
View Article and Find Full Text PDFCorrelation Between Dynamic Contrast-Enhanced CT Imaging Signs and Differentiation Grade and Microvascular Invasion of Hepatocellular Carcinoma.
J Hepatocell Carcinoma
January 2025
School of Medicine, University of Electronic Science and Technology, Sichuan, China.
Objective: This study aimed to investigate how dynamic contrast-enhanced CT imaging signs correlate with the differentiation grade and microvascular invasion (MVI) of hepatocellular carcinoma (HCC), and to assess their predictive value for MVI when combined with clinical characteristics.
Methods: We conducted a retrospective analysis of clinical data from 232 patients diagnosed with HCC at our hospital between 2021 and 2022. All patients underwent preoperative enhanced CT scans, laboratory tests, and postoperative pathological examinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!